₹-27.75
(Market cap
₹93,766 Cr
Recently Viewed
Clear AllMarket cap
₹93,766 Cr
Revenue (TTM)
₹26,089 Cr
P/E Ratio
19
P/B Ratio
3.6
Div. Yield
1.2 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹4,938 Cr
ROE
21.1 %
ROCE
26.1 %
Industry P/E
29.53
EV/EBITDA
11.8
Debt to Equity
0.1
Book Value
₹261
EPS
₹51.5
Face value
1
Shares outstanding
1,006,233,990
CFO
₹26,398.10 Cr
EBITDA
₹35,164.10 Cr
Net Profit
₹23,180.90 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
| -0.3 | 1.7 | 2.1 | 6.1 | 21.0 | 10.1 | 10.8 |
|
BSE Healthcare
| 2.7 | 5.1 | 8.1 | 6.5 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
| -6.1 | 39.0 | 64.1 | -13.1 | 1.0 | 87.5 | -27.4 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zydus Lifesciences
|
911.9 | 93,765.9 | 26,089.3 | 4,933.9 | 24.7 | 21 | 19 | 3.6 |
| 25,300.0 | 54,085.0 | 6,824.1 | 1,524.1 | 25.9 | 37 | 35.5 | 12.3 | |
| 5,408.0 | 63,949.3 | 14,252.7 | 2,424.5 | 17.5 | 19 | 27 | 4.6 | |
| 1,424.7 | 82,337.3 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 23.6 | 2.3 | |
| 362.7 | 58,644.4 | 16,827.4 | 629.6 | 9.6 | -0.1 | 97.1 | 1.5 | |
| 2,420.0 | 41,421.5 | 3,800.7 | 1,021.0 | 32.2 | 55 | 40.6 | 20.7 | |
| 1,533.2 | 39,005.8 | 9,504.5 | 947.8 | 15.9 | 14.6 | 42.9 | 5.0 | |
| 2,297.5 | 1,06,259.9 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.9 | 5.1 | |
| 2,263.6 | 93,546.9 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 52.6 | 6.0 | |
| 1,745.6 | 4,15,996.7 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 38.1 | 5.1 |
Who made the right move - FPI or MF?
4 min read•By Yash Rohra
5 min read•By Jugal Harpalani
1 min read•By Research Desk
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products... segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases. The company offers the products under the Everyuth and Nutralite, Complan, Glucon D, and Nycil brands. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust. Read more
Incorporated
1995
Chairman
Pankaj R Patel
Managing Director
Sharvil P Patel
Group
Cadila
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Zydus Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsIntimation Of Drop In GST Demand
07-Apr-2026Intimation Of Drop In GST Demand
06-Apr-2026No News & Announcements are available.
The share price of Zydus Lifesciences Ltd is ₹911.90 (NSE) and ₹911.30 (BSE) as of 28-Apr-2026 13:54 IST. Zydus Lifesciences Ltd has given a return of 21.01% in the last 3 years.
The P/E ratio of Zydus Lifesciences Ltd is 18.99 times as on 27-Apr-2026, a 36 discount to its peers’ median range of 29.53 times.
The P/B ratio of Zydus Lifesciences Ltd is 3.57 times as on 27-Apr-2026, a 22 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
19.69
|
3.72
|
|
2024
|
26.20
|
5.10
|
|
2023
|
25.37
|
2.84
|
|
2022
|
7.96
|
2.10
|
|
2021
|
21.16
|
3.47
|
The 52-week high and low of Zydus Lifesciences Ltd are Rs 1,059.05 and Rs 835.50 as of 28-Apr-2026.
Zydus Lifesciences Ltd has a market capitalisation of ₹ 93,766 Cr as on 27-Apr-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Zydus Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.